4th International HIV/Viral Hepatitis Co-Infection Meeting

The Rocky Road to Viral Hepatitis Elimination:
Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings

Saturday - Sunday, 22-23 July 2017
Paris, France
Welcome

Bienvenue

Marina Klein, MD, Msc
McGill University Health Centre
Montreal, Canada
International HIV/Viral Hepatitis
Co-Infection Satellite Meeting

18-19 July 2014
Melbourne, Australia

Supporting the HIV, Viral Hepatitis
and Sexual Health Workforce
The DDA Revolution

2015 AASLD/IDSA Guidance: “HIV/HCV co-infection should receive the same treatment as recommended for HCV mono-infection”

5g of diamonds
25 1-carat ($1900 each)
Cost = $48,000

5g of daclatasvir
12 weeks of treatment, 60mg/day
Cost = $53,000 (UK price)

Andrew Hill
2nd International Coinfection Meeting
Vancouver July, 2015
WHO Viral Hepatitis Elimination Strategy

New Infections

Mortality

90% Reduction

65% Reduction

2016

2030
Improving Diagnosis, Antiviral Therapy and Access

• Provide research-based evidence to demonstrate the value of curative therapies
• Engage policy makers towards creating an environment that supports their wider therapeutic access nationally and internationally
• Focus on identifying opportunities for increased diagnosis and treatment of viral hepatitis in PLHIV, particularly in low and middle-income settings.
Treatment Cascade in the Canadian Coinfection Cohort

- Eligible for Treatment
- Initiated Second-Generation DAA
- Sustained Virologic Response

S Saeed, submitted
4th International HIV/Viral Hepatitis Co-Infection Meeting 2017

• Explore the reality faced by people co-infected with HIV and viral hepatitis in high-income countries and across Eastern Europe and Central Asia

• Take stock of scientific breakthroughs and brainstorm on concrete actions to support the WHO targets

• Focus on access to care and DAA treatment especially for key populations with overlapping risk for both HIV and viral hepatitis, such as people who inject drugs, prisoners and men who have sex with men.
Note on the poster exhibition

Most abstracts presented as posters during the 4th International HIV/Viral Hepatitis Co-Infection Meeting are covered by the IAS 2017 embargo policy and therefore cannot be shared externally (e.g., on social media) prior to IAS 2017. The embargo lifts at the presentation of the abstract in the main IAS 2017 conference.
Thanks Merci!

- Co-chair Karine Lacombe
- Scientific Committee
- Sebastien Morin and IAS
- Chantal Burelle
- Funders and supporters